Association of ANKK1 polymorphism with antipsychotic-induced hyperprolactinemia

Olga Yu. Fedorenko1,2 | Diana Z. Paderina1,3 | Anton J. M. Loonen4,5 | Ivan V. Pozhidaev1,3 | Anastasiia S. Boiko1 | Elena G. Kornetova1,6
Nikolay A. Bokhan1,7,8 | Bob Wilffert4,9 | Svetlana A. Ivanova1,2,8

1Mental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russia
2Division for Control and Diagnostics, School of Non-Destructive Testing and Security, National Research Tomsk Polytechnic University, Tomsk, Russia
3Department of Cytology and Genetics, National Research Tomsk State University, Tomsk, Russia
4PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
5Policy Office for Quality and Innovation of Care (BZI), GGZ Westelijk Noord-Brabant, Halsteren, The Netherlands
6Hospital, Siberian State Medical University, Tomsk, Russia
7Department of Psychotherapy and Psychological Counseling, National Research Tomsk State University, Tomsk, Russia
8Department of Psychiatry, Addictology and Psychotherapy, Siberian State Medical University, Tomsk, Russia
9Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Correspondence
Anton J. M. Loonen, Groningen Research Institute of Pharmacy, PharmacoTherapy, -Epidemiology & -Economics, University of Groningen, Antonius Deusinglaan 1, 9713AV Groningen, The Netherlands.
Email: a.j.m.loonen@rug.nl

Funding information
Russian Foundation for Basic Research, Grant/ Award Number: 17-29-06035

Abstract

Objective: Schizophrenia is a severe highly heritable mental disorder. Genetic polymorphisms of dopaminergic pathways are related to pathogenesis of drug response. Hyperprolactinemia (HPRL), a common adverse effect of antipsychotics, is attributed to blockade of dopamine D2 receptors. Ankyrin Repeat and Kinase Domain containing 1 (ANKK1) gene is closely related to Dopamine Receptor D2 type (DRD2) gene functioning. We examined whether the functional polymorphism rs2734849 in the ANKK1 gene is associated with antipsychotic-induced HPRL.

Methods: We recruited 446 patients with schizophrenia from among the Russian population of the Siberian region. The polymorphism rs2734849 in the ANKK1 gene was genotyped with The MassARRAY® Analyzer 4 by Agena Bioscience™, using the kit SEQUENOM Consumables iPLEXGold 384. Genotype and allele frequencies were compared between groups of schizophrenia patients with and without HPRL using the χ² test.

Results: A comparison between schizophrenia patients with and without HPRL revealed significantly higher frequency of the C allele of the polymorphic variant rs2734849 in the ANKK1 gene in patients with HPRL as compared to the patients without it (χ² = 3.70; p = .05; odds ratio [OR] = 1.30 [0.99–1.69]).

Conclusion: The functional polymorphism rs2734849 in the ANKK1 gene was associated with antipsychotic-induced HPRL.

KEYWORDS
ANKK1, hyperprolactinemia, polymorphism, schizophrenia
Schizophrenia is a severe mental disorder characterized by disruptions in thought processes, perceptions, volition, emotional responsiveness, cognitive processes, and social interactions. Antipsychotic drugs targeting dopamine neurotransmission are the principal mean of therapeutic intervention for schizophrenia (Rampino et al., 2019). Hyperprolactinemia (HPRL), a common adverse effect of antipsychotics, is attributed to blockade of dopamine D2 receptors within the pituitary gland (Peusken, Paní, Detraux, & De Hert, 2014).

Since genetic variation in gene coding for proteins that cross-talk with DRD2 at the molecular level are associated with response to antipsychotics (Rampino et al., 2019), the ANKK1 gene (Ankyrin Repeat and Kinase Domain containing 1) is of particular interest. The encoded protein ANKK1, also known as protein kinase PKK2, belongs to a family of serine/threonine kinases involved in a number of signal transduction pathways, including cell proliferation, differentiation, and gene (including DRD2 gene) transcription (Manning, Whyte, Martinez, Hunter, & Sudarsanam, 2002; Neville, Johnstone, & Walton, 2004; Ponce et al., 2009). The most frequently examined in a broad range of psychiatric disorders and personality traits functional polymorphism related to this gene is the Taq1A (rs1800497) (Dubertret et al., 2004; Fossella et al., 2006; Ponce et al., 2009; Suchaneka, Grzywacz, & Samochowiec, 2011; Kenny, Voren, & Johnson, 2013; Nymberg et al., 2014; Treble-Barna et al., 2017; Persson & Stenfors, 2018). It was initially referred to DRD2 but later was shown to be mapped 10 kb downstream of DRD2 in the neighboring gene ANKK1 near the termination codon of the DRD2 on chromosome 11q22-q23 (Dubertret et al., 2010; Neville et al., 2004).

To date, there are inconsistent results from several association studies of ANKK1 polymorphism with schizophrenia and its clinical phenotypes (Alfinova et al., 2017, 2018; Arab & Elhawary, 2015; Eisenstein et al., 2017; Nkam et al., 2017; Parsons et al., 2007; Ponce et al., 2009; Wishart et al., 2011; Yao, Pan, Ding, Pang, & Wang, 2015; Zhang et al., 2014). It has been hypothesized that rs1800497 polymorphism is likely to have a modifying effect rather than causative effect on schizophrenia (Zhang et al., 2014).

DRD2/ANKK1 TaqIA allele status predicts striatal D2R specific binding in humans (Eisenstein et al., 2016; Gluskin & Mickey, 2016).

Interestingly, CYP2D6 metabolic activity affects mean antipsychotics daily dose only in the presence of DRD2 Taq1A polymorphic allele. Subpopulation of schizophrenia inpatients with altered CYP2D6 activity (poor and ultra rapid metabolizers) and when carriers of Taq1A polymorphisms needs special attention of clinicians in aligning of antipsychotic treatment (Kuryljev et al., 2018).

The preliminary epigenetic findings suggest that methylation levels at CpG site 387 of ANKK1 may be associated with the treatment response to aripiprazole in patients with schizophrenia. Furthermore, methylation of ANKK1 may affect dopaminergic neural transmission in the treatment of schizophrenia, and may influence treatment response (Miura et al., 2018).

Next to rs1800497 another functional polymorphism exists in ANKK1 (i.e., rs2734849) which causes a nonsynonymous G to A transition leading to an amino-acid change (arginine to histidine) in C-terminal ankyrin repeat domain of ANKK1 (Huang et al., 2009). There are far fewer data on the possible role of this polymorphism in psychiatric disorders. The exact role of SNP rs2734849 in ANKK1 in psychiatric disorders and drug-induced side effects has yet to be fully characterized.

Using the NF-κB-luciferase reporter assay, Huang et al. (2009) found that the “A” allele of rs2734849 in ANKK1 had greater suppression (~30%) on NF-κB-regulated luciferase activity than the “G” allele of rs2734849 indicating rs2734849 to be a functional polymorphism. In a protein sequence alignment and crystal structure comparison with a 12-ankyrin repeat domain (Michaely, Tomchick, Machius, & Anderson, 2002), they found that the residue at 490 position resides on the surface of protein, a prerequisite for its involvement in mediating protein–protein interaction in the signal-transduction processes leading to inhibition of NF-κB activity.

SNP rs2734849 in ANKK1 is functional in yielding differential suppression of NF-κB-regulated gene expression. Since transcription factor NF-κB is a necessary and sufficient signal factor to induce DRD2 expression (Bontempi et al., 2007; Fiorentini et al., 2002), this suggests that variants of ANKK1, specifically rs2734849, may function to affect DRD2 expression (Huang et al., 2009).

Since dopamine inhibits prolactin secretion by binding to D2 receptors expressed on the cell membrane of the anterior pituitary lactotrophs, we hypothesized that ANKK1 polymorphism modulation of DRD2 expression can be involved in the mechanisms of HPRL induced by antipsychotics due to their high affinity for the D2 receptor. In this study we investigated the association of ANKK1 rs2734849 polymorphism with antipsychotic-induced HPRL in Russian patients with schizophrenia.

2 | MATERIALS AND METHODS

In this study, 446 patients (225 female/221 male) with schizophrenia were included from three psychiatric hospitals in Tomsk, Kemerovo, and Chita oblasts in Siberia, Russian Federation.

The study population and methods applied were previously described by Ivanova, Osmanova, Boiko, et al., 2017, Ivanova, Osmanova, Freidin, et al., 2017. Patients could participate if they had a clinical diagnosis of schizophrenia according to ICD-10 (F20) and were between 18 and 75 years old. Exclusion criteria were a non-Caucasian physical appearance (e.g., Mongoloid, Buryats, or Khakassians), pregnancy, relevant gynecological and endocrine (thyroid) disorders, organic brain disorders (e.g., epilepsy, Parkinson’s disease) or relevant pharmacological withdrawal symptoms.

The study procedures were reviewed and approved by the Local Bioethics Committee of the Mental Health Research Institute. The study was recorded under protocol number N63/7.2014. Patients were included after providing written informed consent. None of the participants was compromised in their capacity to consent; therefore, consent from the next of kin was not recommended by the ethics committee. All works were carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki 1975, revised in Fortaleza, Brazil, 2013) for experiments involving humans.
Depending on the presence of HPRL (vide infra) this group of patients with schizophrenia was divided into two subgroups: 227 patients with HPRL and 219 patients without HPRL.

Patients were treated with conventional and/or atypical antipsychotic drugs in both oral and/or long-acting formulations. One hundred ninety-one patients received conventional antipsychotics. Haloperidol was the most commonly used conventional antipsychotic drug (110 patients). Other conventional antipsychotics included oral chlorpromazine (CPZ), chlorprothixene, trifluoperazine, and zuclopenthixol, and/or long-acting formulations of haloperidol, zuclopenthixol, and flupenthixol. Atypical antipsychotics were used by 176 patients and included risperidone, clozapine, quetiapine, olanzapine, amisulpride, paliperidone, and sertindole. A total of 79 patients used various combinations of classical and atypical drugs. All dosages were converted into CPZ equivalents (CPZeq) to compare the antipsychotic exposure (Andreasen, Pressler, Nopoulos, Miller, & Ho, 2010).

### 2.1 Sampling

Blood samples for DNA extraction and prolactin determination were obtained after 8 hr of overnight fasting. For women of reproductive age, blood was, when possibly, taken in the follicular phase of the menstrual cycle. Blood samples for DNA extraction were collected in EDTA tubes and stored at \(-20^\circ\text{C}\) until DNA isolation. Tubes with clot activator (CAT) were used to obtain serum for measuring prolactin concentrations (BD Vacutainer). The samples were centrifuged for 30 min at 1,500 rpm at 4\(^\circ\text{C}\) to obtain serum.

### 2.2 Biochemical analysis

#### 2.2.1 Prolactin concentration

An accuBind ELISA Microwells kit (Monobind Inc., USA) was used to measure the prolactin concentration. The sensitivity of the used ELISA kit was 0.004 ng/well, what is equivalent to a sample prolactin concentration of 0.150 ng/ml. The upper limits for a normal prolactin concentration were set at ≤20 ng/ml for men and at ≤25 ng/ml for non-pregnant, non-nursing women. These criteria for HPRL were confirmed in literature (Kelly et al., 2013; Peuskens et al., 2014).

#### 2.2.2 DNA analysis

A standard phenol–chloroform micro method (as described by Ivanova et al., 2012) was used to isolate DNA from the leukocytes in the whole peripheral blood samples after pre-freezing of the blood.

Genotyping for ANKK1 rs2734849 was carried out on the MassARRAY® Analyzer 4 (Agena Bioscience™) using the set SEQUENOM Consumables iPLEX Gold 384. DNA sample preparation for SEQUENOM MassARRAY® Analyzer 4 includes several steps: a standard PCR reaction to obtain the amplification products, a shrimp alkaline phosphatase reaction to neutralize the unincorporated dNTPs in the amplification products, the PCR iPLEX Gold extension reaction, and then placing the samples on a special chip (SpectroCHIP Array) using NanoDispenser RS1000 prior to loading them into the analyzer.

### TABLE 1

Demographic and clinical characteristics of patients with schizophrenia (n = 446)

| Trait                                      | All (446) | Male (221) | Female (225) | p-value* |
|--------------------------------------------|-----------|------------|--------------|----------|
| Age (mean ± SD)                            | 42.1 ± 12.4 | 37.8 ± 11.9 | 45.2 ± 13.9  | p < .0001|
| Duration of disease, years Median (IQR)    | 13 (6; 22) | 11 (5; 18) | 15 (7; 26)   | p < .0001|
| Daily dose of antipsychotics in CPZeq Median (IQR) | 425 (240; 750) | 500 (300; 750) | 372 (200; 750) | p < .0001|
| Prolactin ng/ml Median (IQR)               | 23.32 (13.12; 49.96) | 18.18 (10.61; 32.47) | 34.89 (15.50; 65.03) | p < .0001|

**Abbreviations:** CPZeq, chlorpromazine equivalents; IQR, interquartile range.

*Calculated with either the t-test or the Mann–Whitney U test, as appropriate.

### TABLE 2

Frequencies of genotypes and alleles of ANKK1 rs2734849 in schizophrenia patients with and without HPRL (n = 439)

| Genotypes, alleles | Patients with HPRL n (%) | Patients without HPRL n (%) | OR Value 95% CI | χ2 | p |
|--------------------|--------------------------|-----------------------------|-----------------|----|---|
| CC                 | 54 (24.3%)               | 40 (18.4%)                  | 1.42 0.90–2.25  | 3.65 | .16|
| CT                 | 110 (49.5%)              | 105 (48.4%)                 | 1.05 0.72–1.52  |     |    |
| TT                 | 58 (26.1%)               | 72 (33.2%)                  | 0.71 0.47–1.08  |     |    |
| C                  | 218 (49.1%)              | 185 (42.6%)                 | 1.30 0.99–1.69  | 3.70 | .05|
| T                  | 226 (50.9%)              | 249 (57.4%)                 | 0.77 0.59–1.01  |     |    |

**Abbreviations:** 95% confidence interval; ANKK1, Ankyrin Repeat and Kinase Domain containing 1; HPRL, Hyperprolactinemia; OR, odds ratio.
2.3 | Statistics

Data processing and analysis were performed in the Statistical Package for Social Science, version 20.0. The deviation from the Hardy–Weinberg equilibrium was tested with the $\chi^2$ test. To describe the results, frequency distribution tables were used for categorical variables. In the analysis of categorical variables, the Fisher’s exact test was used for the univariate analysis to evaluate the HPRL factors associated to the polymorphism. Differences were considered significant at $p \leq .05$. The adjusted odds ratio (OR) with a respective 95% confidence interval (95% CI) was estimated.

3 | RESULTS

3.1 | Patients

We studied 446 Russian patients (225 female/221 male) with schizophrenia from the Siberian region (Tomsk, Kemerovo, and Chita oblasts). The baseline characteristics of the population are presented in Table 1.

The median dosage of antipsychotic drugs was 425 CPZ equivalents daily and the mean age of the patients was 41.5 years. In general, the mean duration of schizophrenia was 15 years. One hundred ninety-one Patients were treated with conventional antipsychotics (42.8%), 176 patients with atypical antipsychotics (39.5%) and 79 with a combination of conventional and atypical antipsychotics (17.7%). Assuming a lower limit for the presence of HPRL at >25 ng/ml for females and >20 ng/ml for males (Kelly et al., 2013; Peuskens et al., 2014), 227 of the 446 patients suffered from HPRL and 219 patients were without HPRL.

3.2 | Association of ANKK1 rs2734849 with HPRL in the total group of patients with schizophrenia

Of a total group of 446 schizophrenia patients, genotyping results were obtained in 439 patients. The frequency of the rs2734849*C allele of the ANKK1 gene in the total group was significantly higher in patients with HPRL compared to patients with normal level of prolactin (Table 2; $\chi^2 = 3.7; p = 0.05$; OR 1.30; 95%CI: 0.99–1.69). When this group was divided by gender, the rs2734849*C allele of ANKK1 was found to be a relative risk factor for antipsychotic-induced HPRL in female patients only (Table 3; $\chi^2 = 4.17; p = .04$; OR 1.49; 95%CI: 1.02–2.18). No statistically significant associations between ANKK1 rs2734849 and HPRL were observed in the subgroup of male patients with schizophrenia (Table 4).

The analysis of the distribution of prolactin levels depending on the ANKK1 rs2734849 genotypes in patients with schizophrenia did not reveal any statistical differences although there was a tendency.
prolactin levels in patients with schizophrenia carrying CC and CT genotypes (Table 5).

### 3.3 | Association of ANKK1 rs2734849 with HPRL in the subgroup of schizophrenia patients treated with the risperidone/paliperidone

Due to the fact that, HPRL is significantly more common in patients receiving risperidone/paliperidone, the next step was the analysis in the subgroup of patients using the risperidone/paliperidone (n = 75).

No statistically significant associations between ANKK1 rs2734849 and HPRL were found in the subgroup of patients with schizophrenia treated with the risperidone/paliperidone (Table 6).

### 4 | DISCUSSION

A large number of individual genetic association studies have found that the TaqIA SNP in ANKK1 is linked to psychiatric disorders (Ponce et al., 2009).

In this study, we investigated the association between functional polymorphism rs2734849 in ANKK1 gene and antipsychotic-induced HPRL in Russian patients with schizophrenia from the population of Siberia. For the first time we demonstrate that allele rs2734849*T of ANKK1 gene mitigates the risk of antipsychotic-induced HPRL in schizophrenia suggesting for a protective effect against developing this side effect, whereas carriage of the rs2734849*C allele was a relative risk factor for antipsychotic-induced HPRL in schizophrenia. Our results support the involvement of ANKK1 rs2734849 into pathogenesis of antipsychotic-induced HPRL in schizophrenia, although the underlying molecular mechanisms are not clear.

ANKK1 and DRD2 genes belong to the same gene cluster, the NTAD cluster, an ancient cluster of which genes are apparently co-regulated and may have emerged when the central nervous system became more complex (Feistauer, Vitolo, Campagnolo, Mattevi, & Almeida, 2018; Mota, Araujo-Jnr, Paixão-Côrtes, Bortolini, & Bau, 2012). A few in vitro studies with ANKK1 gene mRNAs and proteins were able to show the potential connection between this gene and the dopaminergic system (Feistauer et al., 2018; Garrido et al., 2011; Hoenicka et al., 2007).

There are data about ANKK1 rs2734849 to be functional in yielding differential suppression of NF-κB-regulated gene expression. Since transcription factor NF-κB is a necessary and sufficient signal to induce DRD2 expression (Bontempo et al., 2007; Fiorentini et al., 2002), variants of ANKK1, specifically rs2734849, may affect DRD2 expression (Huang et al., 2009). These findings align with the results that DRD2/ANKK1 gene polymorphisms alter the density of dopamine receptors (Stelzel, Basten, Montag, Reuter, & Fiebach, 2010).

It is known that dopamine holds a predominant role in the regulation of prolactin secretion. It directly inhibits the basally high-secretory tone of the anterior pituitary lactotrophs by binding to D2 receptors expressed on their cell membrane resulting in a reduction of prolactin exocytosis. All typical antipsychotic medications are associated with sustained HPRL due to their high affinity for the D2 receptor and their slow dissociation from the receptor once bound, but atypical antipsychotics are quite dramatically in their propensity causing prolonged high prolactin levels (Fitzgerald & Dinan, 2008). As HPRL directly depends upon the functioning of DRD2 receptors on mammatrophic cells of the anterior pituitary gland (Peuskens et al., 2014), altered functionality of these receptors (particularly altered expression) is more likely to be observed.

Previously in the same sample of patients we studied a set of 41 SNPs of genes encoding the dopamine receptors DRD1, DRD2, DRD3, DRD4, the dopamine transporter SLC6A3, and dopamine catabolizing enzymes MAOA and MAOB (Fedorenko et al., 2017; Osmanova et al., 2019). No associations were found between the DRD2 gene polymorphism and the antipsychotic-induced HPRL in patients with schizophrenia. We have demonstrated the MAOB rs1799836 to be a potential risk factor for HPRL in men in the total group (Osmanova et al., 2019).

In the current study we hypothesize that in the total group of patients with schizophrenia those who carry rs2734849*C allele of ANKK1 gene have higher density of D2 receptors on the anterior pituitary lactotrophs resulting in HPRL induced by antipsychotics due to their high affinity for the D2 receptors.

Risperidone is known to elevate prolactin due to its higher peripheral-to-central dopamine receptor potency (Fitzgerald & Dinan, 2008); Geers et al., 2020). Earlier in the same sample of patients we

---

### TABLE 6  Analysis of association between HPRL and ANKK1 rs2734849 in patients with schizophrenia from risperidone/paliperidone group (n = 75)

| Genotype, alleles | Patients with HPRL n (%) | Patients without HPRL n (%) | OR Value | 95% CI | $\chi^2$ | $p$ |
|------------------|--------------------------|----------------------------|----------|-------|--------|-----|
| CC               | 14 (23.7)                | 3 (18.8)                   | 1.35     | 0.34–5.42 | 2.58   | .28 |
| CT               | 28 (47.5)                | 5 (31.3)                   | 1.99     | 0.61–6.43 |        |     |
| TT               | 17 (28.8)                | 8 (50.0)                   | 0.40     | 0.13–1.25 |        |     |
| C                | 56 (47.5)                | 11 (34.4)                  | 1.72     | 0.76–3.89 | 1.74   | .19 |
| T                | 62 (52.5)                | 21 (65.6)                  | 0.58     | 0.26–1.31 |        |     |

Abbreviations: 95% confidence interval; ANKK1, Ankyrin Repeat and Kinase Domain containing 1; HPRL, Hyperprolactinemia; OR, odds ratio.
have found that the rs40184 and rs3863145 variants in SLC6A3 gene appeared to be associated with HPRL in the subgroup of patients using the risperidone/paliperidone, but not with HPRL induced by other antipsychotic drugs (Osmanova et al., 2019). However, when only patients treated with risperidone/paliperidone were studied, no significant association was found with ANKK1 rs2734849 polymorphism (Table 6). Another limitation of the study might be our reluctance to analyze genotyping data of ANKK1 in combination with other genes. We genotyped a few other genes in much the same patient sample and in the same run (Geers et al., 2020; Ivanova, Osmanova, Freidin, et al., 2017; Osmanova et al., 2019), but this analysis would be insufficiently extensive and hypothesis-driven. Our results extend previous findings about association of ANKK1 with antipsychotic-induced side effects.

5 | CONCLUSION

The results of this study indicate that the prevalence of antipsychotic-induced HPRL in Russian patients with schizophrenia is higher in carriers of rs2734849*C allele of ANKK1 gene whereas allele rs2734849*T of ANKK1 gene has a protective effect against antipsychotic-induced HPRL in this sample. Further investigation will be required to develop a better understanding of the mechanisms by which ANKK1 gene polymorphism influence the drug-induced side effects in schizophrenia.

ACKNOWLEDGMENTS

This study was supported by the grant #17-29-06035 “New approaches to the pharmacogenetics of antipsychotic-induced hyperprolactinemia in patients with schizophrenia.” This work was carried out within the framework of Tomsk Polytechnic University Competitiveness Enhancement Program.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

ORCID

Olga Yu. Fedorenko https://orcid.org/0000-0002-9565-6314
Diana Z. Paderina https://orcid.org/0000-0002-5546-7316
Anton J. M. Loonen https://orcid.org/0000-0003-4942-6195
Ivan V. Pozhidaev https://orcid.org/0000-0003-1238-7495
Anastasia S. Boiko https://orcid.org/0000-0002-2955-9057
Elena G. Kornetova https://orcid.org/0000-0002-5179-9727
Nikolay A. Bokhan https://orcid.org/0000-0002-1052-855X
Bob Wilffert https://orcid.org/0000-0002-8759-5697
Svetlana A. Ivanova https://orcid.org/0000-0001-7078-323X

REFERENCES

Alfimova, M. V., Golimbet, V. E., Korovaitseva, G. I., Lezheiko, T. V., Tikhonov, D. V., Ganisheva, T. K., ... Shemiakina, T. K. (2017). A role of interactions between N-methyl-D-aspartate and dopamine receptors in facial emotion recognition impairment in schizophrenia. Zhurnal Nevrologii i Psikiatrii Imeni S.S. Korakova, 11(7), 47–52. https://doi.org/10.17116/jnevro20171116147-52
Alfimova, M. V., Korovaitseva, G. I., Lezheiko, T. V., Golubev, S. A., Snegireva, A. A., Sakharova, E. A., & Golimbet, V. E. (2018). The interaction effect of ANKK1/DRD2 TaqIA and HTR2C Cys235Ser on approach motivation in schizophrenic patients and normals. Zhurnal Nevrologii i Psikiatrii Imeni S.S. Korakova, 11(8), 67–72. https://doi.org/10.17116/jnevro20181187167
Andreasen, N. C., Pressler, M., Nopoulos, P., Miller, D., & Ho, B. C. (2010). Antipsychotic dose equivalents and dose-years: A standardized method for comparing exposure to different drugs. Biological Psychiatry, 67(3), 255–262. https://doi.org/10.1016/j.biopsych.2009.08.040
Arab, A. H., & Elhawary, N. A. (2015). Association between ANKK1 (rs1800497) and LTA (rs909253) genetic variants and risk of schizophrenia. BioMed Research International, 2015, 1–8. https://doi.org/10.1155/2015/821827
Bontempi, S., Fiorentini, C., Busi, C., Guerra, N., Spano, P., & Missale, C. (2007). Identification and characterization of two nuclear factor-kappaB sites in the regulatory region of the dopamine D2 receptor. Endocrinology, 148, 2563–2570. https://doi.org/10.1210/en.2006-1618
Dubertret, C., Bardel, C., Ramoz, N., Martin, P. M., Deybach, J. C., Ades, J., ... Gouya, L. (2010). A genetic schizophrenia-susceptibility region located between the ANKK1 and DRD2 genes. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 34, 492–499. https://doi.org/10.1016/j.pnpbp.2010.02.003
Dubertret, C., Gouya, L., Hanoun, N., Deybach, J. C., Ades, J., Hamon, M., & Gorwood, P. (2004). The 3’ region of the DRD2 gene is involved in genetic susceptibility to schizophrenia. Schizophrenia Research, 67(1), 75–85.
Eisenstein, S. A., Bogdan, R., Chen, L., Moerlein, S. M., Black, K. J., Perlmutter, J. S., ... Barch, D. M. (2017). Preliminary evidence that negative symptom severity relates to multifocal genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia. Journal of Psychiatric Research, 86, 9–17. https://doi.org/10.1016/j.jpsychires.2016.11.007
Eisenstein, S. A., Bogdan, R., Love-Gregory, L., Corral-Frias, N. S., Koller, J. M., Black, K. J., ... Hershey, T. (2016). Prediction of striatal D2 receptor binding by DRD2/ANKK1 allele status. Synapse, 70(10), 418–431. https://doi.org/10.1002/syn.21916
Fedorenko, O. Y., Loonen, A. J. M., Vyalova, N. M., Boiko, A. S., Pozhidaev, I. V., Osmanova, D. Z., ... Ivanova, S. A. (2017). Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia. Physiologiya i Farmakologiya, 21(1), 25–33.
Feistauer, V., Vitolo, M. R., Campagnolo, P. D. B., Mattevi, V. S., & Almeida, S. (2018). Evaluation of association of DRD2 TaqIA and -141C InsDel polymorphisms with food intake and anthropometric data in children at the first stages of development. Genetics and Molecular Biology, 41(3), 562–569. https://doi.org/10.1590/1679-4685-GMB-2017-0202
Fiorentini, C., Guerra, N., Facchetti, M., Finardi, A., Tiberio, L., Schiaffonati, L., ... Missale, C. (2002). Nerve growth factor regulates dopamine D2 receptor expression in prolactinoma cell lines via p75 NGF receptor-mediated activation of nuclear factor-kappaB. Molecular Endocrinology, 16, 353–366. https://doi.org/10.1210/men.16.2.0773
Fitzgerald, P., & Dinan, T. G. (2008). Prolactin and dopamine: what is the connection? A review article. Journal of Psychopharmacology, 22(25suppl), 12–19. https://doi.org/10.1177/0269768407087148
Fossella, J., Green, A. E., & Fan, J. (2006). Evaluation of a structural polymorphism in the ankyrin repeat and kinase domain containing 1 (ANKK1) gene and the activation of executive attention networks. Cognitive, Affective & Behavioral Neuroscience, 6(1), 71–78. https://doi.org/10.3758/cabn.6.1.71
Garrido, E., Palomo, T., Ponce, G., Garcia-Consuegra, I., Jimenez-Arriero, M. A., & Hoenicka, J. (2011). The ANKK1 protein associated with addictions has nuclear and cytoplasmic localization and...
polymorphisms and schizophrenia: A meta-analysis. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 168B(1), 1-13. https://doi.org/10.1002/ajmg.b.32281

Zhang, C., Zhang, J., Fan, J., Cheng, W., Du, Y., Yu, S., & Fang, Y. (2014). Identification of ANKK1 rs1800497 variant in schizophrenia: New data and meta-analysis. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 165B(7), 564-571. https://doi.org/10.1002/ajmg.b.32259

How to cite this article: Fedorenko OY, Paderina DZ, Loonen AJM, et al. Association of ANKK1 polymorphism with antipsychotic-induced hyperprolactinemia. Hum Psychopharmacol Clin Exp. 2020;e2737. https://doi.org/10.1002/hup.2737